Study population We included all patients registered as having type 2 diabetes in the National Diabetes Register who filled their first prescription for a GLP-1 receptor agonist, and, in a separate cohort, all patients registered as having type 2 diabetes in the National Diabetes Register who filled their first prescription for an SGLT2 inhibitor, between 1 January 2017 and 31 December 2021 (ensuring a minimum of 1-year follow-up until the end of the study period on 31 December 2022)
Recently, the Wegovy pill, an oral semaglutide option, was approved by the FDA, providing more choices for those who prefer not to inject
Other viable treatment options for weight loss include: Diethylpropion Liraglutide Naltrexone-bupropion extended-release (ER) Phentermine Phentermine-topiramate extended-release (ER) Consult your doctor to explore which weight loss medication is right for you
GSH is a primary cellular antioxidant composed of glutamate, cysteine and glycine
Email: [email protected]
This is due to beta-alanine's stimulation of certain nerve receptors just under the skin, leading to sensations that some users describe as tingling or prickly feeling